Novo Nordisk (NYSE: NVO) reported Q4 EPS of DKK6.34. Revenue for the quarter came in at DKK85.68 billion.

OUTLOOK

2025 outlook, sales growth is expected to be 16-24% at CER, and operating profit growth is expected to be 19-27% at CER. Sales and operating profit growth reported in Danish kroner is expected to be 3 and 5 percentage points higher than at CER, respectively.

For earnings history and earnings-related data on Novo Nordisk (NVO) click here.